GENTIBIO

gentibio-logo

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to... successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.

#SimilarOrganizations #People #Financial #Event #Website #More

GENTIBIO

Social Links:

Industry:
Biotechnology Life Science

Founded:
2020-01-01

Address:
Seattle, Washington, United States

Country:
United States

Website Url:
http://www.gentibio.com

Total Employee:
1+

Status:
Active

Total Funding:
177 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Wordpress Plugins Nginx Sitelinks Search Box


Similar Organizations

aavantibio-logo

AavantiBio

AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

novellus-logo

Novellus

Novellus is a biotechnology company working to develop engineered cellular medicines.

renovacor-logo

Renovacor

Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapyโ€‘based treatments for cardiovascular disease.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.


Current Advisors List

nathaniel-brooks-horwitz_image

Nathaniel Brooks Horwitz Board Director @ GentiBio
Board_member
2020-01-01

Current Employees Featured

adel-nada_image

Adel Nada
Adel Nada Co-founder, President and CEO @ GentiBio
Co-founder, President and CEO
2020-01-01

andy-walker_image

Andy Walker
Andy Walker Co-founder & Chief Technology Officer @ GentiBio
Co-founder & Chief Technology Officer
2020-01-01

chandra-patel_image

Chandra Patel
Chandra Patel Co-founder, Vice President R&D Operations @ GentiBio
Co-founder, Vice President R&D Operations
2020-01-01

neely-mozaffarian_image

Neely Mozaffarian
Neely Mozaffarian Chief Medical Officer @ GentiBio
Chief Medical Officer
2022-06-01

chuck-silberstein_image

Chuck Silberstein
Chuck Silberstein Chief Financial Officer @ GentiBio
Chief Financial Officer
2022-02-01

Founder


adel-nada_image

Adel Nada

andy-walker_image

Andy Walker

chandra-patel_image

Chandra Patel

Investors List

jdrf-t1d-fund_image

JDRF T1D Fund

JDRF T1D Fund investment in Series A - GentiBio

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series A - GentiBio

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series A - GentiBio

avidity-partners_image

Avidity Partners

Avidity Partners investment in Series A - GentiBio

seattle-children-s-hospital-and-research-institute_image

Seattle Children's Hospital and Research Institute

Seattle Children's Hospital and Research Institute investment in Series A - GentiBio

matrix-capital-management_image

Matrix Capital Management

Matrix Capital Management investment in Series A - GentiBio

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series A - GentiBio

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Seed Round - GentiBio

orbimed-advisors_image

OrbiMed

OrbiMed investment in Seed Round - GentiBio

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Seed Round - GentiBio

Official Site Inspections

http://www.gentibio.com

  • Host name: 141.193.213.11
  • IP address: 141.193.213.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "GentiBio"

Home - GentiBio

Sep 30, 2024 GentiBioโ€™s engineering augments Tregs function and optimizes their manufacturing to create powerful and tailored therapeutics for autoimmune and inflammatory โ€ฆSee details»

GentiBio - Crunchbase Company Profile & Funding

GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or โ€ฆSee details»

Our Team - GentiBio

David Rawlings, MD. Director, Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Scientific Co-founder and Senior Scientific AdvisorSee details»

GentiBio - LinkedIn

GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat ...See details»

GentiBio 2025 Company Profile: Valuation, Funding

When was GentiBio founded? GentiBio was founded in 2020. Where is GentiBio headquartered? GentiBio is headquartered in Cambridge, MA. What is the size of GentiBio? GentiBio has 61 total employees. What industry is GentiBio in? โ€ฆSee details»

About - GentiBio

GentiBioโ€™s Tregs: the future of immunology therapeutics. Our goal is to replace the need for systemic and less selective immune suppressive therapies and their associated risks. โ€ฆSee details»

Gentibio, Inc. Company Profile | Seattle, WA - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Gentibio, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»

GentiBio - Funding, Financials, Valuation & Investors - Crunchbase

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases. New. Resources. Advanced Search. ... How much funding โ€ฆSee details»

GentiBio - VentureRadar

" GentiBio, Inc., is an emerging biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells programmed to treat โ€ฆSee details»

GentiBio - Contacts, Employees, Board Members, Advisors & Alumni

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases. ... Experience the new Crunchbase, powered by AI . โ€ฆSee details»

GentiBio Company Profile - Office Locations, Competitors ... - Craft

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its โ€ฆSee details»

GentiBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Explore GentiBio, Inc. with its drug pipeline, therapeutic area, technology platform, 27 news, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, Immune System Diseases, โ€ฆSee details»

GentiBio - Overview, News & Similar companies | ZoomInfo.com

Oct 10, 2022 Who is GentiBio. GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and all โ€ฆSee details»

Company: Gentibio

Gentibio is a biotechnology company focused on advancing the use of autologous regulatory T cells (Tregs) to treat human disease. Gentibioโ€™s scientific approach involves gene editing โ€ฆSee details»

Our Platform - GentiBio

Tissue targeting. Problem: Tregs require selective targeting to diseased tissues to direct and maintain their potent suppressive properties to the right location, thus optimizing safety and โ€ฆSee details»

GentiBio Company Overview, Contact Details & Competitors

GentiBio. Biotechnology Research Massachusetts, United States 51-200 Employees. GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and โ€ฆSee details»

GentiBio - Work in biotech

GentiBio is developing engineered regulatory T cells (Tregs). Tregs are the bodyโ€™s natural means for keeping the immune system in balance. Tregs suppress potentially pathogenic immune โ€ฆSee details»

GentiBio Announces $157M Series A Financing to Advance โ€ฆ

BOSTON, MA โ€“ August 11, 2021 . GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has โ€ฆSee details»

Company Spotlight: GentiBio - Medium

Sep 9, 2021 GentiBio is an early stage, privately held biotech company, founded in 2020. The company is focused on developing new therapies to regulate aberrantly functioning immune โ€ฆSee details»

Boston Biotech Startup Raises $20M in Funding, Licenses T Cell ...

Image: Shutterstock. On Wednesday, biotech startup GentiBio launched with $20 million in seed funding.. Headquartered in Boston, the company draws on technologies licensed from a โ€ฆSee details»

linkstock.net © 2022. All rights reserved